Janika Viereck studied biotechnology and journalism. During her PhD and Postdoc at the Institute of Molecular and Translations Therapeutic Strategies, Hannover Medical School, Germany (2012 – 2017) she focused on long non-coding RNAs and microRNAs as potential drug as well as diagnostic targets for the treatment and diagnosis of cardiovascular disease. She developed inhibitory oligonucleotide approaches to therapeutically modulate non-coding RNA function. In 2017 she moved to industry and became R&D manager at Cardior Pharmaceuticals GmbH, Germany, a clinical stage biopharmaceutical company focused on the discovery, development and clinical validation of noncoding RNA therapeutics as innovative medicines for patients with various forms of heart failure. She is responsible for the preclinical development of oligonucleotide-based therapeutics.